TP53 and adrenal cortex carcinoma: In order to identify potential genetic modifiers underlying ACC development that could improve cancer risk management and treatment, we genotyped a total of 42 TP53 R337H carriers with ACC, divided into a discovery cohort (BRZ1, N = 26) and a validation cohort (BRZ2, N = 16).